Sonnet BioTherapeutics Stockholders Approve Business Combination With Hyperliquid Strategies And Rorschach I

Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) ("Sonnet" or the "Company") today announced that its stockholders approved, among other things, the proposed business combination with Hyperliquid Strategies Inc ("HSI") and Rorschach I LLC at its special meeting of stockholders.

The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission.